AU2017380213B2 - Crystalline forms of a janus kinase inhibitor - Google Patents

Crystalline forms of a janus kinase inhibitor Download PDF

Info

Publication number
AU2017380213B2
AU2017380213B2 AU2017380213A AU2017380213A AU2017380213B2 AU 2017380213 B2 AU2017380213 B2 AU 2017380213B2 AU 2017380213 A AU2017380213 A AU 2017380213A AU 2017380213 A AU2017380213 A AU 2017380213A AU 2017380213 B2 AU2017380213 B2 AU 2017380213B2
Authority
AU
Australia
Prior art keywords
composition
crystalline
compound
added
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017380213A
Other languages
English (en)
Other versions
AU2017380213A1 (en
Inventor
Yukihiro Kamiya
Satoru Noji
Ryuhei OKURA
Noriaki SHIMOYAMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AU2017380213A1 publication Critical patent/AU2017380213A1/en
Application granted granted Critical
Publication of AU2017380213B2 publication Critical patent/AU2017380213B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017380213A 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor Active AU2017380213B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
US62/437,262 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Publications (2)

Publication Number Publication Date
AU2017380213A1 AU2017380213A1 (en) 2019-05-23
AU2017380213B2 true AU2017380213B2 (en) 2022-01-06

Family

ID=60991475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017380213A Active AU2017380213B2 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Country Status (13)

Country Link
US (1) US11339181B2 (enExample)
EP (1) EP3559003B1 (enExample)
JP (3) JP2020502224A (enExample)
KR (1) KR102788829B1 (enExample)
CN (2) CN121045220A (enExample)
AU (1) AU2017380213B2 (enExample)
BR (1) BR112019012210A2 (enExample)
CA (1) CA3044771A1 (enExample)
ES (1) ES2926986T3 (enExample)
IL (1) IL267393B2 (enExample)
MX (1) MX386181B (enExample)
TW (1) TWI822666B (enExample)
WO (1) WO2018117153A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3560932A4 (en) 2016-12-21 2020-10-28 Japan Tobacco, Inc. PROCESS FOR THE PRODUCTION OF A 7H-PYROLLO [2,3-D] PYRIMIDINE DERIVATIVE AND ITS SYNTHETIC INTERMEDIATE
KR20220044288A (ko) * 2019-08-07 2022-04-07 로토 세이야쿠 가부시키가이샤 누액 분비 촉진용 안과 조성물
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
JP2022120834A (ja) * 2021-02-05 2022-08-18 ロート製薬株式会社 シェーグレン症候群治療剤
AU2022319128A1 (en) * 2021-07-30 2024-01-18 Eli Lilly And Company Treatment of hand eczema with baricitinib
EP4673216A1 (en) * 2023-02-28 2026-01-07 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136778A1 (en) * 2009-07-31 2011-06-09 Japan Tobacco Inc. Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090296332A1 (en) * 2005-07-07 2009-12-03 Thomson Licensing Flat-Screen Display System With Corresponding Sleeves
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
PT2432472T (pt) * 2009-05-22 2019-12-09 Incyte Holdings Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrilo como inibidores de jak
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
JP6427497B2 (ja) * 2013-10-21 2018-11-21 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
CN107709337B (zh) 2015-07-07 2021-11-16 日本烟草产业株式会社 7H-吡咯并[2，3-d]嘧啶衍生物的制备方法和其中间体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110136778A1 (en) * 2009-07-31 2011-06-09 Japan Tobacco Inc. Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Balbach S. et al., Pharmaceutical evaluation of early development candidates "The 100 mg approach", International Journal of Pharmaceutics, 2004, Vol. 275, pages 1-12 *
CAIRA M.R: "Crystalline Polymorphism of Organic Compounds", Design of Organic solids, Weber E et al "ED", Springer, 1998 *
Singhal, D. et al., Drug polymorphism and dosage form design: a practical perspective, Advanced Drug Delivery Reviews, 2004, Vol. 56, pages 33 *

Also Published As

Publication number Publication date
MX2019007462A (es) 2019-08-29
US20200017527A1 (en) 2020-01-16
CN110325536A (zh) 2019-10-11
KR102788829B1 (ko) 2025-03-31
ES2926986T3 (es) 2022-10-31
RU2019122566A3 (enExample) 2021-12-22
CA3044771A1 (en) 2018-06-28
AU2017380213A1 (en) 2019-05-23
MX386181B (es) 2025-03-18
BR112019012210A2 (pt) 2019-11-12
CN121045220A (zh) 2025-12-02
IL267393B2 (en) 2023-07-01
US11339181B2 (en) 2022-05-24
WO2018117153A1 (en) 2018-06-28
RU2019122566A (ru) 2021-01-22
JP2024161449A (ja) 2024-11-19
IL267393B1 (en) 2023-03-01
EP3559003A1 (en) 2019-10-30
TW201829423A (zh) 2018-08-16
KR20190092440A (ko) 2019-08-07
JP2020502224A (ja) 2020-01-23
IL267393A (en) 2019-08-29
JP2023024729A (ja) 2023-02-16
EP3559003B1 (en) 2022-08-24
TWI822666B (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
AU2017380213B2 (en) Crystalline forms of a janus kinase inhibitor
CA3026602C (en) Pyrrolopyrimidine crystal for the preparation of a JAK inhibitor
US11555038B2 (en) Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
EP4332102A1 (en) Isoquinolone compound and use thereof
AU2019338032A1 (en) Salts of substituted pyrrolopyrimidine CDK inhibitor, crystal and use thereof
EP4134366A1 (en) 3-azabicycloalkyl derivative and pharmaceutical composition containing same
EP3851439A1 (en) Furo[3,4-b]pyrrole-containing btk inhibitor
CA2979157A1 (en) Crystalline compound as semicarbazide-sensitive amine oxidase (ssao) enzyme inhibitor
US12065441B2 (en) Pyrazolopyrimidine derivative, use thereof and pharmaceutical composition
EP4293018A1 (en) Compound serving as nlrp3 inhibitor
EP4169915A1 (en) Crystalline form of compound
RU2838992C2 (ru) Кристаллические формы ингибитора янус-киназы
US20210198211A1 (en) Crystalline eltrombopag monoethanolamine salt form d
US20230399331A1 (en) Solid forms of jak inhibitor and process of preparing the same
US20230192710A1 (en) Jak inhibitor compound and use thereof
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
BR122024025362A2 (pt) Formas cristalinas de um inibidor de janus cinase, composição farmacêutica compreendendo as ditas formas cristalinas, seu uso e métodos de medição
WO2022117012A1 (zh) 螺环jak抑制剂、含其的药物组合物及其应用
HK40050819A (en) Ebna1 inhibitor crystalline forms, and methods of preparing and using same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)